nach oben

Erschienen in:

17.11.2021 | COVID-19 | COVID-19 Zur Zeit gratis

Rhino-orbito-cerebral mucormycosis during the COVID-19 third wave in 2021: an Egyptian preliminary report from a single tertiary hospital

verfasst von: Taha K. Alloush, Osama Mansour, Adel T. Alloush, Tamer Roushdy, Eman Hamid, Mahmoud El-Shamy, Hossam M. Shokri

Erschienen in: Neurological Sciences | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

COVID-19 is a pandemic disease which predominantly affects the respiratory system with high critical care mortality and morbidity; however, it also causes multi-organ dysfunction in a subset of patients. Although causality between COVID-19 and mucormycosis remains unclear, many factors including glucocorticoids, worsening of blood glucose control, and viral-induced lymphopenia have been attributed to cause mucormycosis in patients with COVID-19. In COVID-19 patients, especially those who need oxygen support, inflammatory and cytokine storm or usage of steroids make the immune system weak. This may pave the way for opportunistic infections including mucormycosis. We report fourteen cases of COVID-19 infection, who developed rhino-orbito-cerebral mucormycosis, during treatment. Early recognition of this life-threatening infection is the key to allow for optimal treatment and improved outcomes.

Spellberg B, Edwards J, Jr., Ibrahim, A. (2005) Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 18:556–569CrossRefPubMedPubMedCentral

Werthman-Ehrenreich A (2020) Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. https://doi.org/10.1016/j.ajem.2020.09.032CrossRefPubMedPubMedCentral

He J, Sheng G, Yue H, Zhang F, Zhang HL (2021) Isolated pulmonary mucormycosis in an immunocompetent patient: a case report and systematic review of the literature. BMC Pulm Med 21:138CrossRefPubMedPubMedCentral

Chandra, S.; Sharma, S.; Vats, R.; Pandey, S. Isolated cerebral mucormycosis masquerading as a tumor in an immunocompetent patient. Autops. Case Rep. 2021, 11, e2020233.

Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP (2012) Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 54 (Suppl S1)S23–S34

Pan AS, Srinath L (2013) Mucormycosis in a patient with AIDS receiving systemic steroids. J Am Osteopath Assoc 113:708–711PubMed

Droll A, Kunz F, Passweg JR, Michot M (2004) Cerebral mucormycosis in a patient with myelodysplastic syndrome taking corticosteroids. Br J Haematol 126:441CrossRefPubMed

Hoang K, Abdo T, Reinersman JM, Lu R, Higuita NIA (2020) A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient. Med Mycol Case Rep 29:22–24CrossRefPubMedPubMedCentral

Prakash H, Ghosh AK, Rudramurthy SM et al (2019) A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol 57(4):395–402. https://doi.org/10.1093/mmy/myy060CrossRefPubMed

10.

Mantero V, Basilico P, Pozzetti U, Tonolo S, Rossi G, Spena G, Rigamonti A, Salmaggi A (2020) Concomitant cerebral aspergillosis and mucormycosis in an immunocompetent woman treated with corticosteroids. J Neurovirol 26:277–280CrossRefPubMed

11.

Sharma S, Grover M, Bhargava S, Samdani S, Kataria T (2021) Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol:1–6

12.

Prakash H, Chakrabarti A (2021) Epidemiology of mucormycosis in India Microorganisms 9(3):523. https://doi.org/10.3390/microorganisms9030523CrossRefPubMed

13.

Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A (2020) COVID -19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 22:1935–1941. https://doi.org/10.1111/dom.14057CrossRefPubMed

14.

Majumdar K. A potentially lethal fungal disease is creeping into recovering COVID-19 patients, and the prognosis is not good. https://www.businessinsider.i n/science/health/news/a-potentially-lethal-fungal-di sease-is-creeping-into-recovering-COVID-19-patient s-and-the-prognosis-is-not-good/articleshow/824763 75.cms. Accessed May 15, 2021.

15.

Mehta S, Pandey A (2020) Rhino-orbital mucormycosis associated with COVID-19. Cureus 12(9):e10726. https://doi.org/10.7759/cureus.10726CrossRefPubMedPubMedCentral

16.

Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG (2021) Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol 69(2):244–252CrossRefPubMedPubMedCentral

17.

Mishra N, Mutya VSS, Thomas A (2021) A case series of invasive mucormycosis in patients with COVID-19 infection. Int J Otorhinolaryngol Head Neck Surg;7(5):867–870. [Google Scholar]

18.

Pasero D, Sanna S, Liperi C et al (2020) A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection Published online. https://doi.org/10.1007/s15010-020-01561-xCrossRef

19.

do Monte Junior ES, dos Santos MEL, Ribeiro IB et al (2020) Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: a case report. Clin Endosc 53:746–749. https://doi.org/10.5946/ce.2020.180CrossRefPubMedCentral

20.

Mekonnen ZK, Ashraf DC, Jankowski T et al (2021) Acute invasive rhinoorbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthal Plast Reconstr Surg 37:e40–e80. https://doi.org/10.1097/IOP.0000000000001889CrossRefPubMed

21.

Satish D, Joy D, Ross A (2021) Balasubramanya Mucormycosis coinfection associated with global COVID-19: a case series from India. Int J Otorhinolaryngol Head Neck Surg 7(5):815–820. [Google Scholar]

22.

Hanley B, Naresh KN, Roufosse C et al (2020) Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe 1:e245–e253. https://doi.org/10.1016/S2666-5247(20)30115-4CrossRefPubMedPubMedCentral

23.

Raut A, Huy NT (2021) Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? Lancet Respir Med. https://doi.org/10.1016/S2213-2600(21)00265-4CrossRefPubMedPubMedCentral

24.

Bhogireddy, Ramadevi et al. “Is Mucormycosis an inevitable complication of Covid-19 in India?” The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases vol. 25,3 (2021): 101597. https://doi.org/10.1016/j.bjid.2021.101597

25.

Singh AK, Singh R, Joshi SR, Misra A (2021) Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 15(4):102146. doi: https://doi.org/10.1016/j.dsx.2021.05.019. Epub 2021 May 21. PMID: 34192610; PMCID: PMC8137376.

26.

Skiada A, Pavlovas I, Drogari-Apiranthitou M (2020) Epidemiology and diagnosis of mucormycosis: an update. J Fungi 6:265. https://doi.org/10.3390/jof6040265CrossRef

27.

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B et al (2019) Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and Research consortium. Lancet Infect Dis 19(12):e405–e421CrossRefPubMedPubMedCentral

28.

Masoud HH, Elassal G, Zaky S, Abdel Baki A. Management protocol for COVID-19 patients version 1.4/30th May 2020 Ministry of Health and population (MOHP), Egypt. In book: Coronavirus disease 2019(COVID-19), SARSCOV2 management guideline. Publisher: Ministry of Health and Population, http://www.mohp.gov.eg/JobsDetails.aspx?job_id=3061.

29.

Honavar, Santosh G. Code Mucor. Indian Journal of Ophthalmology: June 2021 - Volume 69 - Issue 6 - p 1361–1365. https://doi.org/10.4103/ijo.IJO_1165_21

30.

Mahalaxmi I, Jayaramayya K, Venkatesan D, Subramaniam MD, Renu K, Vijayakumar P, Narayanasamy A, Gopalakrishnan AV, Kumar NS, Sivaprakash P, Sambasiva Rao KRS, Vellingiri B (2021) Mucormycosis: an opportunistic pathogen during COVID-19. Environ Res 201:111643. https://doi.org/10.1016/j.envres.2021.111643. Epub ahead of print. PMID: 34237335; PMCID: PMC8258024

31.

Waldorf AR (1989) Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser 47:243–271PubMed

32.

Diamond RD, Haudenschild CC, Erickson NF (1982) Monocytemediated damage to Rhizopus oryzae hyphae in vitro. Infect Immun 38:292–297. https://doi.org/10.1128/IAI.38.1.292-297.1982CrossRefPubMedPubMedCentral

33.

Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP (2012) Pathogenesis of mucormycosis. Clin Infect Dis 54:S16–S22. https://doi.org/10.1093/cid/cir865CrossRefPubMedPubMedCentral

34.

Chinn RY, Diamond RD (1982) Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 38:1123–1129. https://doi.org/10.1128/IAI.38.3.1123-1129.1982CrossRefPubMedPubMedCentral

35.

Müller JA, Groß R, Conzelmann C et al (2021) SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab 3:149–165. https://doi.org/10.1038/s42255-021-00347-1CrossRefPubMed

36.

Pal R, Banerjee M (2020) COVID-19 and the endocrine system: exploring the unexplored. J Endocrinol Invest 43:1027–1031. https://doi.org/10.1007/s40618-020-01276-8CrossRefPubMedPubMedCentral

37.

Pal R, Bhadada SK (2020) COVID-19 and diabetes mellitus: an unholy interaction of two pandemics. Diabetes Metab Syndr Clin Res Rev 14:513–517. https://doi.org/10.1016/j.dsx.2020.04.049CrossRef

38.

Rehman K, Akash MSH, Liaqat A, Kamal S, Qadir MI, Rasul A (2017) Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr 27:229–236. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2017019712CrossRefPubMed

39.

Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L (2020) SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev 54:62–75. https://doi.org/10.1016/j.cytogfr.2020.06.001CrossRefPubMedPubMedCentral

40.

John TM, Jacob CN, Kontoyiannis DP (2021) When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi 7:298. https://doi.org/10.3390/jof7040298CrossRef

41.

Pal R, Singh B, Bhadada SK et al (2021) COVID-19-associated mucormycosis: an updated systematic review of literature. Mycoses 00:1–8. https://doi.org/10.1111/myc.13338CrossRef

42.

Pretorius E, Kell DB (2014) Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases. Integr Biol 6:486–510. https://doi.org/10.1039/C4IB00025KCrossRef

43.

Habib HM, Ibrahim S, Zaim A, Ibrahim WH (2021) The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators. Biomed Pharmacother 136:111228. https://doi.org/10.1016/j.biopha.2021.111228CrossRefPubMedPubMedCentral

44.

Perricone C, Bartoloni E, Bursi R et al (2020) COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunol Res 68:213–224. https://doi.org/10.1007/s12026-020-09145-5CrossRefPubMedPubMedCentral

45.

Ibrahim AS, Spellberg B, Edwards J (2008) Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 21:620–625. https://doi.org/10.1097/QCO.0b013e3283165fd1CrossRefPubMedPubMedCentral

46.

Rammaert B, Lanternier F, Zahar J-R et al (2012) Healthcare-associated mucormycosis. Clin Infect Dis. 54:S44–S54. https://doi.org/10.1093/cid/cir867CrossRefPubMed

47.

Hosseini SM, Borghei P (2005) Rhinocerebral mucormycosis: pathways of spread. Eur Arch Otorhinolaryngol 262(11):932–938CrossRefPubMed

48.

Gamaletsou MN, Sipsas NV, Roilides E, Walsh TJ (2012) Rhino-orbital-cerebral mucormycosis. Curr Infect Dis Rep 14(4):423–434CrossRefPubMed

49.

Abdollahi A, Shokohi T, Amirrajab N et al (2016) Clinical features, diagnosis, and outcomes of rhino-orbito-cerebral mucormycosis- a retrospective analysis. Curr Med Mycol 2(4):15–23. https://doi.org/10.18869/acadpub.cmm.2.4.15CrossRefPubMedPubMedCentral

50.

Johnson E Van, Kline LB, Julian BA et al(1988) Bilateral cavernous sinus thrombosis due to mucormycosis. Arch Ophthalmol 106:1089–1092. [PubMed] [Google Scholar]

51.

Grant P, Skilbeck CJ (2014) Rhinocerebral mucormycosis: a devastating rhinological condition. Practical Diabetes 31(1):37–39CrossRef

52.

Spelberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS (2009) Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 48(12):1743–1751CrossRef

53.

Pagano L, Ricci P, Tonso A et al (1997) Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. Br J Haematol 99(2):331–336. https://doi.org/10.1046/j.1365-2141.1997.3983214.xCrossRefPubMed

54.

Sukaina M (2021) Re-emergence of mucormycosis in COVID-19 recovered patients transiting from silent threat to an epidemic in India. Journal of Global Health Reports 5:e2021067. https://doi.org/10.29392/001c.25479CrossRef

55.

Madney Y, Khedr R, Ahmed N, El-Mahallawy H, Youssef A, Taha H et al (2019) Overview and outcome of mucormycosis among children with cancer: report from the Children’s Cancer Hospital Egypt. Mycoses 62(11):984–989. https://doi.org/10.1111/myc.12915CrossRefPubMed

56.

Zaki SM, Elkholy IM, Elkady NA, Abdel-Ghany K (2014) Mucormycosis in Cairo, Egypt: review of 10 reported cases. Med Mycol. 52(1):73–80. https://doi.org/10.3109/13693786.2013.809629CrossRefPubMed

57.

El-Kholy N, Musaad A, Khafagy Y (2021) Invasive fungal sinusitis in post COVID -19 patients: a new clinical entity. Laryngoscope. https://doi.org/10.1002/lary.29632CrossRefPubMedPubMedCentral

58.

Ebeid K, Gamea M, Allam A, Shehata E (2021) Impact of COVID-19 on acute invasive fungal rhinosinusitis: a comparative study. Egyptian Journal of Ear, Nose, Throat and Allied Sciences 22(22):1–7. https://doi.org/10.21608/ejentas.2021.76357.1369CrossRef

59.

Fouad YA, Abdelaziz TT, Askoura A, Saleh MI, Mahmoud MS, Ashour DM, Ashour MM (2021) Spike in rhino-orbital-cerebral mucormycosis cases presenting to a tertiary care center during the COVID-19 pandemic. Front Med 8:645270. https://doi.org/10.3389/fmed.2021.645270CrossRef

60.

Roushdy T, Hamid E (2021) A case series of post COVID-19 mucormycosis-a neurological prospective. Egypt J Neurol Psychiatr Neurosurg 57(1):100. https://doi.org/10.1186/s41983-021-00355-8. Epub 2021 Jul 26. PMID: 34335016; PMCID: PMC8312207

61.

Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, Singh R, Shastri P, Umabala P, Sardana R et al (2020) A multi-centre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect 26(944):e9-944.e15

Titel: Rhino-orbito-cerebral mucormycosis during the COVID-19 third wave in 2021: an Egyptian preliminary report from a single tertiary hospital
verfasst von: Taha K. Alloush
Osama Mansour
Adel T. Alloush
Tamer Roushdy
Eman Hamid
Mahmoud El-Shamy
Hossam M. Shokri
Publikationsdatum: 17.11.2021
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Neurological Sciences / Ausgabe 2/2022
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-021-05740-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Crossed cerebellar diaschisis after acute ischemic stroke detected by intravoxel incoherent motion magnetic resonance imaging

Neuro-oncology and supportive care: the role of the neurologist

Disease severity and response to treatment in Iranian patients with myasthenia gravis

First report of a homozygous mutation on exon 24 of the NOTCH3 gene in a paucisymptomatic CADASIL elderly patient

Rapidly progressive dementia and intractable diarrhea: a teaching case report and a systematic review of cognitive impairment in Whipple’s disease